NASDAQ : TENX

Tenax Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Details

NameTenax Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees16
Founded1967
CeoChristopher Giordano
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS88032L6056
Cusip88032L605
Cik0000034956
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Christopher T. GiordanoChief Executive Officer, President and Director
Thomas A. McGauleyPrincipal Financial Officer and Principal Accounting Officer
Dr. Stuart Rich M.D.Chief Medical Officer and Director
Thomas R. Staab II, CPAChief Financial Officer
Doug RandallChief Business Officer
Dr. Douglas Hay Ph.D.Executive Vice President of Regulatory Affairs
Timothy G. Healey M.B.A.Chief Commercial Officer
Dr. So-Young Kim M.D.Executive Vice President of Clinical Development and Strategy

Contact

Address101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517, United States
Phone919 855 2100
Websitehttps://www.tenaxthera.com